共 176 条
[1]
January CT(2019)2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R J Am Coll Cardiol 74 104-132
[2]
Wann LS(2018)Anticoagulant therapy in atrial fibrillation for stroke prevention: assessment of agreement between clinicians’ decision and CHA2DS2-VASc and HAS-BLED Scores High Blood Press Cardiovasc Prev. 25 61-64
[3]
Calkins H(2018)The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation Eur Heart J. 39 1330-1393
[4]
Chen LY(2018)2018 focused update of the canadian cardiovascular society guidelines for the management of atrial fibrillation Can J Cardiol 34 1371-1392
[5]
Cigarroa JE(2020)Factors affecting trough plasma dabigatran concentrations in patients with atrial fibrillation and chronic kidney disease High Blood Press Cardiovasc Prev. 27 151-156
[6]
Cleveland JCJ(2005)Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas Stroke 36 1588-1593
[7]
Balaghi-Inalou M(2007)Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review QJM 100 599-607
[8]
Parsa SA(2007)Newly detected atrial fibrillation and compliance with antithrombotic guidelines Arch Intern Med. 167 246-252
[9]
Gachkar L(2007)Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial Lancet 370 493-503
[10]
Andalib S(2013)RE-LY Dabigatran vs Warfarin AF N Engl J Med. 368 2355-2365